According to the release, PPD noted that wearable technology will have the potential to benefit Novartis and its other clients because of the integration with the technologies patients use on a daily basis.
Clinical Ink, a provider of eSource solutions for clinical trials, announced that CentrosHealth, a mobile patient engagement platform, now includes streamlined connectivity for a wide range of medical devices. This new platform was developed with cooperation from Novartis and PPD, who are also supporting a pilot clinical study before broad commercial use. According to the release, PPD noted that wearable technology will have the potential to benefit Novartis and its other clients because of the integration with the technologies patients use on a daily basis. Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.